NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report)’s share price was up 6.7% during trading on Tuesday. The stock traded as high as $11.49 and last traded at $12.26. Approximately 326 shares traded hands during trading, a decline of 85% from the average session volume of 2,170 shares. The stock had previously closed at $11.49.
NewAmsterdam Pharma Stock Performance
The company’s 50 day simple moving average is $15.78 and its two-hundred day simple moving average is $19.68.
Institutional Investors Weigh In On NewAmsterdam Pharma
An institutional investor recently bought a new position in NewAmsterdam Pharma stock. Headlands Technologies LLC acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 72,335 shares of the company’s stock, valued at approximately $1,546,000.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.
Read More
- Five stocks we like better than NewAmsterdam Pharma
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
